On October 18, 2022 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biologics for the treatment of cancer and neuropathy, reported that the first adult patient has been dosed in the Pilot Proof of Concept Pharmacokinetic/Pharmacodynamic (PK/PD) Study in Cancer Patients (RETRO) (Press release, Bexion, OCT 18, 2022, View Source [SID1234622157]). The study will examine the effects of BXQ-350 on cancer patients exposed to Oxaliplatin and/or Taxane-based chemotherapy exhibiting chemotherapy-induced peripheral neuropathy (CIPN) symptoms.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are delighted with the news that the first patient has been dosed in our Phase 1 RETRO study. This study is a natural follow-on to data reported from our recent Phase 1 solid tumor study in cancer patients, in which patients reported potential reduction of existing CIPN symptoms," said Scott Shively, Chief Executive Officer of Bexion Pharmaceuticals. "CIPN is an enormous problem in which over 700,000 surviving cancer patients per year in the US alone have peripheral neuropathies caused by their prior chemotherapy. We are targeting to have initial data read-out from this study in 3Q2023."
The aim of this pilot proof-of-concept study is to assess PK/PD relationships in cancer patients with CIPN symptoms to determine the impact BXQ-350 has on ceramide, S1P, and inflammatory cytokine levels; thereby potentially reducing the intensity and/or duration of CIPN, improving quality of life, and establishing these signaling molecules as biomarkers in future studies.
The trial is being conducted at CTI Clinical Research Center in Cincinnati, Ohio. The plan is to enroll twenty patients. Interested patients can find more information here: View Source